Section Arrow
ANAB.NASDAQ
- AnaptysBio
Quotes are at least 15-min delayed:2026/06/20 19:51 EDT
Regular Hours
Last
 57.51
+0.74 (+1.30%)
Day High 
58.44 
Prev. Close
56.77 
1-M High
64.355 
Volume 
827.83K 
Bid
53.06
Ask
63
Day Low
55.16 
Open
58.37 
1-M Low
50.06 
Market Cap 
1.65B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 54.13 
20-SMA 55.27 
50-SMA 56.91 
52-W High 72.36 
52-W Low 11.402444 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.02/2.86
Enterprise Value
1.66B
Balance Sheet
Book Value Per Share
0.44
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
234.60M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.01+0.0056+127.27%-- 
CDTCDT Equity Inc.1.02+0.327+47.19%-- 
AZTRAzitra0.1717-0.0313-15.42%-- 
CRVOCervoMed4.24+0.43+11.29%-- 
OCGNOcugen1.24+0.01+0.81%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.